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Abstract
Six acetophenone derivatives, acronyculatins I (1), J (2), K (3), L (4), N (5), and O (6), were 
recently isolated from Acronychia trifoliolata, and the structure of the known acronyculatin B (7) 
was revised. Because of the limited quantities of isolated products as well as their structure 
similarity, racemic acronyculatins I–L, N, O, and B (1–7) were synthesized to confirm their 
structures and to obtain sufficient material for biological evaluation. Trihydroxyacetophenone was 
converted to the target compounds by various sequences of hydroxy group protection, allylation or 
prenylation, and epoxidation followed by cyclization. C-Prenylations were carried out by direct 
addition of a prenyl group or through 1,3- or 3,3-sigmatropic rearrangement. The synthesized 
racemic compounds were evaluated in an anti-tumor-promoting assay using the Epstein–Barr virus 
early antigen (EBV-EA) activation induced by 12-O-tetradecanoylphorbol-13-acetate in Raji cells. 
All tested compounds significantly inhibited EBV-EA activation. Especially, racemic 
acronyculatin I (1) displayed the most potent inhibitory effects, with an IC50 value of 7.3 μM.
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Prenylated acetophenones are mainly distributed in specific genera of the Rutaceae, such as 
Acradenia, Bosistoa, Melicope, Medicosma, and Acronychia.1 In rare cases, they are found 
in the root bark of Derris indica2 and Brazilian propolis.3 More than 50 prenylated 
acetophenones have been isolated from the above species.1 The prenyl group(s) is 
sometimes cyclized with a neighboring phenolic oxygen to form a pyran or furan ring. 
Interesting dimeric acetophenones, such as acrove-stone, acropyrone, and acropyraonols, are 
found only in Acronychia.4–8
Acronychia trifoliolata Zoll. & Moritzi is distributed from Java and Christmas Island to the 
Solomon Islands, and only one phytochemical study has been reported on this species.7 In 
the course of the discovery of unknown bioactive natural products from rainforest plants, six 
new acetophenone monomers, named acronyculatins I (1), J (2), K (3), L (4), M, N (5), and 
O (6), were isolated from a 1:1 CH3OH/CH2Cl2 extract of this plant.9 In addition, the 
structure of acronyculatin B (7), originally identified by Su et al.,10 was revised to be 1-[6-
hydroxy-2-(2-hydroxypropan-2-yl)-4-methoxy-7-(3-methylbut-2-en-1-yl)-2,3-
dihydrobenzofuran-5-yl]ethan-1-one based on extensive NMR studies. Because the isolation 
was performed on a limited amount (4.9 g) of extract provided by the U.S. National Cancer 
Institute (NCI), and no more material was available, small quantities of each compound were 
obtained. However, all isolated compounds were successfully identified using various NMR, 
HRMS, and IR techniques. Compounds 1–7 showed weak or no antiproliferative activity.9 
However, prior studies have indicated that acetophenone derivatives display potent inhibition 
of tumor-promoting activities.11,12 In addition, the importance of a prenyl-like functional 
group was discussed in our previous reports.13–16 Thus, prenylated acetophenones, such as 
the acronyculatins, could significantly inhibit the tumor-promoting activities. To confirm the 
structure elucidation as well as provide sufficient quantities of materials for further 
bioassays, the total syntheses of racemic acronyculatins 1–7 were performed. Herein, the 
synthesis details and evaluation of the anti-tumor-promoting activities are described.
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RESULTS AND DISCUSSION
Since acetophloroglucinol is the core skeleton for all target compounds, 2,4,6-
trihydroxyacetophenone (8) was selected as the starting material. Scheme 1 illustrates the 
synthesis of acetophenone monomers 1–5. Two hydroxy groups of trihydroxyacetophenone 
(8) were first protected as methoxymethyl (MOM) ethers to provide 9. Prenylation of the 
hydrogen-bonded phenolic group, followed by microwave-assisted para-Claisen 
rearrangement, produced 10,17 which was methylated with MeI to generate 11. The selective 
removal of only one MOM protecting group was achieved successfully by controlled 
reaction conditions in 3 N HCl/MeOH (1:10 v/v) solution. Treatment of 1218 with m-
chloroperoxybenzoic acid (m-CPBA) afforded an epoxide, and subsequent cyclization to the 
chromane 14 was catalyzed by montmorillonite K10 clay.19 The removal of the remaining 
MOM group, prenylation of the phenolic group, and 1,3-rearrangement of the prenyl group 
using montmorillonite K1020 gave racemic acronyculatin L (4). Racemic acronyculatin K 
(3) was synthesized similarly from 11. Both MOM groups were removed by using more 
concentrated acidic conditions [3 N HCl/MeOH (1:5 v/v)] than those mentioned above for 
the selective removal of one MOM group. Two subsequent reactions (mCPBA, 
montmorillonite K10 clay) on the resulting 1318,21 produced only 16, in which cyclization 
had occurred via the non-hydrogen-bonded hydroxy group. The O-prenylation and 
microwave-assisted para-Claisen rearrangement of 16 gave racemic acronyculatin K (3). 
Catalytic reduction of 3 produced unnatural compound 18, a regioisomer of 2.
Compound 8 was treated with prenyl bromide in the presence of 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU)22 to generate monoprenylated acetophenone 19, 
which was converted to 20 by MOM protection, methylation, and deprotection of MOM 
groups. Dihydroxyacetophenone 20 was treated with mCPBA and montmorillonite K10 clay 
to afford 21. Prenylation of the phenolic group and subsequent 1,3-rearrangement gave 
racemic acronyculatin I (1), which was converted to racemic acronyculatin J (2) by catalytic 
reduction. Racemic acronyculatin M (5) was prepared from di-MOM ether 9. O-Allylation 
of the phenolic group and subsequent microwave-assisted 3,3-sigmatropic rearrangement of 
the allyl ether produced 22. Deprotection of both MOM groups gave 23. Oxidative cleavage 
of the terminal olefinic bond was followed by spontaneous hemiacetalization to provide 5.
As shown in Scheme 2, the prenylation of trihydroxyacetophenone 8 in the presence of 10% 
KOH produced diprenylated acetophenone 24, which was converted to 25 through a three-
step sequence, i.e., disilylation using tert-butyldimethylsilyl chloride (TBSCl), methylation, 
and selective deprotection23 of the TBS ether. Treatment of 25 with 1 molar equiv of 
mCPBA at low temperature resulted in nonselective monoepoxidation of the olefinic 
functional groups. The resulting two products were probably the dihydrobenzofuran 31, 
which was spontaneously cyclized through 27a, and epoxide 27b. To avoid the unfavorable 
cyclization, the phenolic moiety on 25 was protected as the acetate to give 26. The 
monoepoxidation of 26 under the above conditions afforded 28a and 28b as an inseparable 
ca. 1:3 mixture by 1H NMR analysis. The removal of the TBS group with tetra-n-
butylammonium fluoride (TBAF)/HOAc prompted cyclization to the separable 
dihydrobenzofurans 29 and 30 in 27% and 64% yield, respectively. Under the same 
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conditions, no chromane type of product was obtained, while the use of KF/18-crown-6/TFA 
at −10 °C generated 32 as a minor product and dihydrobenzofurans 29 and 30. Hydrolysis of 
the acetoxy group of 29 and 30 by using Ba(OH)2 generated racemic acronyculatins O (6) 
and B (7) in 56% and 53% yield, respectively.
The structures of the compounds were defined via HRMS and NMR data and were 
consistent with the assigned structures of the compounds9 isolated from A. trifoliolata Zoll. 
& Moritzi.
As mentioned above, previous studies have indicated that prenyl-like structures and 
acetophenone derivatives tend to show potent effects on inhibition of 12-O-
tetradecanoylphor-bol-13-acetate (TPA)-mediated tumor-promoting activity.11–16 Thus, 
compounds 1–7, 18, 29, and 30 were evaluated for cancer chemopreventive activity by 
means of the Epstein–Barr virus early antigen (EBV-EA) activation stimulated by TPA in 
Raji cells. It has been proven that inhibitory effects on EBV-EA activation correlate well 
with anti-tumor-promoting activity in vivo, as was previously reported for several natural 
product derivatives, such as the analogues of dimethyl biphenyldicar-boxylate,13 betulinic 
acid,15,24 and coumarins.16,25
As shown in Table 3, the tested compounds displayed low to moderate cytotoxicity, as 
shown by high viability (60%) of Raji cells, implying less than 40% growth inhibition, even 
at a high concentration of TPA (32 nmol, a compound/TPA molar ratio of 1000:1). 
Furthermore, all compounds significantly inhibited TPA-mediated EBV-EA activation. 
Racemic acronyculatin I (1) showed the most potent inhibitory activity, with 100% 
inhibition of EBV-EA activation at the highest concentration (1000 mol ratio/TPA) and 7.6% 
inhibition at the lowest tested concentration (10 mol ratio/TPA). The IC50 value was 7.3 μM. 
Among the phenolic compounds 1–7 and 18, compound 5, devoid of a prenyl group, clearly 
exhibited reduced activity. These data supported the previous observations that a prenyl or 
prenyl-like group plays an important role in anti-tumor-promoting effects. Interestingly, the 
position of functional groups slightly affected the activity in the case of compounds with a 
chromane skeleton (1 vs 3 and 2 vs 18), while no difference was observed between the two 
compounds with a dihydrobenzofuran skeleton (6 vs 7). In addition, with the latter two 
compounds, the absence of a phenolic group led to decreased activity (6 vs 29 and 7 vs 30).
In summary, seven racemic acronyculatins isolated from A. trifoliolata Zoll. & Moritzi. and 
the acetophenone monomer 18 were synthesized. The NMR spectra of the synthetic racemic 
acronyculatins B and I–O were identical to those of the natural products. Evaluation of anti-
tumor-promoting activity revealed that all tested acetophenones significantly inhibited EBV-
EA activation induced by TPA in Raji cells. Especially, racemic acronyculatin I (1) 
displayed the most potent activity.
EXPERIMENTAL SECTION
General Experimental Procedures
Optical rotations were recorded on a JASCO P-2200 digital polarimeter. Infrared spectra 
(IR) were measured with a Shimadzu FTIR-8700 instrument for samples in CHCl3. NMR 
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spectra were acquired on JEOL JMN-ECA600 and JMN-ECS400 spectrometers with 
tetramethylsilane as internal standard, and chemical shifts are expressed as δ values. HRMS 
data were obtained on a JMS-SX102A (FAB) or JMS-T100TD (DART) mass spectrometer. 
Microwave irradiation experiments were carried out in a dedicated Biotage Initiator 2.5 
microwave apparatus. Analytical and preparative TLC was carried out on precoated silica 
gel 60F254 and RP-18F254 plates (0.25 or 0.50 mm thickness; Merck). MPLC was performed 
with silica gel and C18 cartridges (Biotage, Uppsala Sweden). Compounds 9–1316,17,20 and 
1921 were obtained previously.
1-[3-Hydroxy-7-methoxy-5-(methoxymethoxy)-2,2-dimethylchroman-8-
yl]ethanone (14)—To a solution of 12 (27.4 mg, 0.09 mmol) in anhydrous CH2Cl2 (2.0 
mL) was added 75% m-CPBA (25.2 mg, 0.11 mmol) at 0 °C, and the mixture was stirred for 
20 min at room temperature. After consumption of 12 (TLC), montmorillonite K10 (27.3 
mg) was added and stirring was continued for 30 min at room temperature. The mixture was 
filtered and washed with EtOAc. The organic layer was washed with saturated Na2CO3, 
H2O, and brine, dried over Na2SO4, and concentrated in vacuo. The residue was 
chromatographed on silica gel with EtOAc/n-hexane (1:2) to afford 14 (20.0 mg, 69%) as a 
yellow oil: 1H NMR (600 MHz, CDCl3) δ 6.33 (1H, s), 5.20 (2H, s), 3.79–3.76 (1H, m), 
3.77 (3H, s), 3.49 (3H, s), 2.87 (1H, dd, J = 16.8, 5.4 Hz), 2.65 (1H, dd, J = 17.4, 6.0 Hz), 
2.46 (3H, s), 1.75 (1H, d, J = 7.2 Hz), 1.33 (3H, s), 1.31 (3H, s); 13C NMR (150 MHz, 
CDCl3) δ 201.7, 157.2, 156.3, 151.1, 114.3, 101.6, 94.4, 90.9, 77.5, 69.1, 56.2, 56.0, 32.6, 
26.1, 24.6, 21.8; HRMS (FAB) m/z 311.1499 [M + H]+ (calcd for C16H23O6, 311.1495).
1-(3,5-Dihydroxy-7-methoxy-2,2-dimethylchroman-8-yl)-ethanone—To a solution 
of 14 (20.0 mg, 0.06 mmol) in anhydrous MeOH (1.5 mL) was added 3 N HCl (0.3 mL), 
and the mixture was refluxed for 1.0 h under N2. After cooling to room temperature, the 
mixture was stirred for 15 min. The reaction was quenched with H2O and extracted with 
EtOAc (3 × 10 mL). The combined organic layers were washed with brine, dried over 
Na2SO4, and concentrated in vacuo. The residue was chromatographed on silica gel with 
EtOAc/n-hexane (1:1) to afford the deprotected compound (16.0 mg, 93%) as a colorless 
solid: 1H NMR (600 MHz, CDCl3) δ 6.00 (1H, s), 5.28 (1H, brs), 3.82–3.80 (1H, m), 3.70 
(3H, s), 2.84 (1H, dd, J = 16.8, 4.8 Hz), 2.62 (1H, dd, J = 18.0, 6.6 Hz), 2.47 (3H, s), 1.91 
(1H, d, J = 6.0 Hz), 1.34 (3H, s), 1.32 (3H, s); 13C NMR (150 MHz, acetone-d6) δ 199.3, 
156.8, 156.1, 151.6, 112.8, 100.7, 91.4, 77.5, 68.7, 55.1, 31.8, 26.0, 25.1, 19.4; HRMS 
(FAB) m/z 267.1227 [M + H]+ (calcd for C14H19O5, 267.1232).
1-[3-Hydroxy-7-methoxy-2,2-dimethyl-5-(3-methylbut-2-enyloxy)chroman-8-
yl]ethanone (15)—To a solution of 1-(3,5-dihydroxy-7-methoxy-2,2-dimethylchroman-8-
yl)ethanone (10.9 mg, 0.04 mmol) and K2CO3 (23.0 mg, 0.17 mmol) in acetone (1.0 mL) 
was added prenyl bromide (0.07 mL, 0.06 mmol). The mixture was heated under reflux for 
2.0 h under N2. After cooling to room temperature, the mixture was filtered, washed with 
EtOAc, and concentrated in vacuo. The residue was chromatographed on silica gel with 
EtOAc/n-hexane (1:2) to afford 15 (10.4 mg, 76%) as a yellow oil: 1H NMR (600 MHz, 
CDCl3) δ 6.07 (1H, s), 5.46–5.44 (1H, m), 4.53 (2H, d, J = 6.6 Hz), 3.79 (3H, s), 3.79–3.76 
(1H, m), 2.85 (1H, dd, J = 16.8, 5.4 Hz), 2.63 (1H, dd, J = 17.4, 6.0 Hz), 2.47 (3H, s), 1.79 
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(3H, s), 1.75 (3H, s), 1.73 (1H, d, J = 7.2 Hz), 1.33 (3H, s), 1.30 (3H, s); 13C NMR (150 
MHz, CDCl3) δ 201.7, 158.9, 156.5, 151.3, 138.0, 119.5, 113.3, 100.9, 89.0, 77.5, 69.1, 
65.2, 56.0, 32.6, 26.1, 25.8, 24.6, 21.8, 18.3; HRMS (FAB) m/z 335.1860 [M + H]+ (calcd 
for C19H27O5, 335.1858).
(rac)-Acronyculatin L (4)—To a solution of 15 (10.4 mg, 0.03 mmol) in anhydrous 
CH2Cl2 (0.5 mL) was added montmorillonite K10 (10.3 mg) at 0 °C. The mixture was 
heated in a microwave instrument at 60 °C for 4.0 h. The mixture was filtered, washed with 
EtOAc, and concentrated in vacuo. The residue was purified using preparative TLC with 
EtOAc/n-hexane (3:5) to afford the target 4 [4.9 mg, 66% (based on recovery of starting 
material)] as a yellow oil: 1H NMR (600 MHz, CDCl3) δ 5.74 (1H, s), 5.23–5.20 (1H, m), 
3.80–3.78 (1H, m), 3.71 (3H, s), 3.35 (2H, d, J = 7.2 Hz), 2.87 (1H, dd, J = 16.8, 4.8 Hz), 
2.65 (1H, dd, J = 16.8, 5.4 Hz), 2.50 (3H, s), 1.85 (3H, s), 1.79 (3H, s), 1.74 (1H, brs), 1.34 
(3H, s), 1.32 (3H, s); 13C NMR (600 MHz, CDCl3) δ 202.2, 155.5, 154.5, 149.5, 136.3, 
121.9, 118.2, 111.8, 103.6, 77.5, 69.1, 63.5, 32.7, 26.2, 25.9, 24.7, 22.8, 21.9, 18.0; HRMS 
(FAB) m/z 335.1850 [M + H]+ (calcd for C19H27O5, 335.1858).
1-(3,5-Dihydroxy-7-methoxy-2,2-dimethylchroman-6-yl)-ethanone (16)—To a 
solution of 13 (48.2 mg, 0.19 mmol) in anhydrous CH2Cl2 (3.0 mL) was added 75% m-
CPBA (53.2 mg, 0.23 mmol) at 0 °C, and the mixture was stirred for 20 min at room 
temperature. After complete consumption of 13 (TLC), montmorillonite K10 (48.3 mg) was 
added and the mixture was further stirred for 30 min at room temperature. The mixture was 
filtered and washed with EtOAc. The organic layer was washed with saturated Na2CO3(aq), 
H2O, and brine, dried over Na2SO4, and concentrated in vacuo. The residue was 
chromatographed on silica gel with EtOAc/n-hexane (1:2) to afford 16 (31.3 mg, 61%) as a 
colorless solid: 1H NMR (600 MHz, CDCl3) δ 14.4 (1H, s), 5.90 (1H, s), 3.85–3.82 (1H, m), 
3.83 (3H, s), 2.87 (1H, dd, J = 16.8, 4.8 Hz), 2.65 (1H, dd, J = 16.8, 5.4 Hz), 2.61 (3H, s), 
1.61 (1H, d, J = 6.6 Hz), 1.39 (3H, s), 1.33 (3H, s); 13C NMR (150 MHz, CDCl3) δ 203.2, 
165.2, 161.5, 159.5, 105.6, 99.3, 91.1, 78.4, 69.1, 55.4, 32.9, 25.4, 24.8, 22.2; HRMS (FAB) 
m/z 267.1241 [M + H]+ (calcd for C14H19O5, 267.1232).
1-[3-Hydroxy-7-methoxy-2,2-dimethyl-5-(3-methylbut-2-enyloxy)chroman-6-
yl]ethanone (17)—To a solution of 16 (27.9 mg, 0.10 mmol) and K2CO3 (58 mg, 0.42 
mmol) in acetone (2.0 mL) was added prenyl bromide (0.02 mL, 0.15 mmol), and the 
mixture was heated at reflux temperature for 20 h under N2. The mixture was cooled to 
room temperature, filtered, washed with EtOAc, and concentrated in vacuo. The residue was 
purified using preparative TLC with CHCl3/MeOH (20:1) to afford 17 (28.3 mg, 81%) as a 
colorless oil: 1H NMR (600 MHz, CDCl3) δ 6.21 (1H, s), 5.47–5.45 (1H, m), 4.35 (2H, d, J 
= 7.2 Hz), 3.81–3.79 (1H, m), 3.76 (3H, s), 2.92 (1H, dd, J = 16.8, 4.8 Hz), 2.70 (1H, dd, J = 
16.8, 5.4 Hz), 2.50 (3H, s), 1.77 (3H, s), 1.67 (3H, s), 1.65 (1H, s), 1.36 (3H, s), 1.32 (3H, 
s); 13C NMR (150 MHz, CDCl3) δ 202.1, 156.5, 155.9, 155.2, 138.8, 119.8, 118.9, 105.4, 
96.2, 91.1, 71.6, 69.3, 55.7, 32.6, 26.3, 25.8, 24.7, 22.0, 18.1; HRMS (FAB) m/z 335.1854 
[M + H]+ (calcd for C19H27O5, 335.1858).
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(rac)-Acronyculatin K (3)—A solution of 17 (26.4 mg, 0.08 mmol) in N,N-diethylaniline 
(0.5 mL) was heated in a microwave instrument at 210 °C for 1.0 h. After cooling to room 
temperature, the mixture was washed with aqueous 10% HCl, H2O, and brine, dried over 
Na2SO4, and concentrated in vacuo. The residue was chromatographed on silica gel with 
EtOAc/n-hexane (1:5) to afford 3 (18.5 mg, 70%) as a yellow oil: 1H NMR (600 MHz, 
CDCl3) δ 13.6 (1H, s), 5.15–5.13 (1H, m), 3.85–3.83 (1H, m), 3.71 (3H, s), 3.26 (2H, t, J = 
5.4 Hz,), 2.91 (1H, dd, J = 17.4, 5.4 Hz), 2.68 (1H, dd, J = 17.4, 6.0 Hz), 2.69 (3H, s), 1.77 
(3H, s), 1.68 (3H, s), 1.62 (1H, d, J = 7.2 Hz), 1.37 (3H, s), 1.32 (3H, s); 13C NMR (150 
MHz, CDCl3) δ 203.4, 162.1, 159.1, 158.1, 131.1, 123.2, 115.0, 108.6, 103.2, 78.2, 68.9, 
62.7, 30.9, 25.8, 25.7, 24.8, 22.5, 22.1, 18.0; HRMS (FAB) m/z 335.1852 [M + H]+ (calcd 
for C19H27O5, 335.1858).
1-(3,5-Dihydroxy-8-isopentyl-7-methoxy-2,2-dimethylchroman-6-yl)ethanone 
(18)—To a solution of 3 (8.1 mg, 0.02 mmol) in EtOH (0.5 mL) was added Pd/C (3.3 mg). 
The reaction mixture was sealed and stirred at room temperature for 2.0 h under H2. The 
mixture was filtered through Celite, washed with EtOAc, and concentrated in vacuo. The 
residue was purified using preparative TLC with CHCl3/MeOH (30:1) to afford the target 18 
(5.9 mg, 72%) as a yellow oil: 1H NMR (400 MHz, CDCl3) δ 13.6 (1H, s), 3.84 (1H, q, J = 
4.8 Hz), 3.72 (3H, s), 2.90 (1H, dd, J = 16.8, 5.4 Hz), 2.68 (1H, dd, J = 17.4, 6.0 Hz), 2.68 
(3H, s), 2.55–2.51 (2H, m), 1.63–1.60 (2H, m), 1.40–1.37 (1H, m), 1.38 (3H, s), 1.33 (3H, 
s), 0.97 (3H, s), 0.95 (3H, s); 13C NMR (150 MHz, CDCl3) δ 203.4, 161.9, 159.1, 158.1, 
116.3, 108.6, 103.1, 78.1, 68.9, 62.9, 39.2, 30.9, 28.4, 25.9, 24.9, 22.6, 22.6, 22.1, 21.3; 
HRMS (FAB) m/z 337.1975 [M + H]+ (calcd for C19H29O5, 337.2015).
1-[2-Hydroxy-4,6-bis(methoxymethoxy)-3-(3-methylbut-2-enyl)phenyl]ethanone
—To a solution of 19 (167.5 mg, 0.71 mmol) in anhydrous CH2Cl2 (5.0 mL) was added 
N,N-diisopropylethylamine (0.35 mL, 2.01 mmol) at 0 °C, and the mixture was stirred for 
20 min under Ar. MOMCl (0.13 mL, 1.71 mmol) was added, and stirring at room 
temperature continued for 45 min. The reaction was quenched with H2O and extracted with 
CH2Cl2 (3 × 10 mL). The combined organic layers were washed with brine, dried over 
Na2SO4, and concentrated in vacuo. The residue was chromatographed on silica gel with 
CH2Cl2/n-hexane (1:1) to afford the target di-MOM ether (149.2 mg, 65%) as a pale yellow 
solid: 1H NMR (600 MHz, CDCl3) δ 13.8 (1H, s), 6.39 (1H, s), 5.25 (2H, s), 5.23 (2H, s), 
5.21–5.18 (1H, m), 3.51 (3H, s), 3.47 (3H, s), 3.30 (2H, d, J = 7.2 Hz), 2.65 (3H, s), 1.78 
(3H, s), 1.66 (3H, s); 13C NMR (150 MHz, CDCl3) δ 203.5, 163.5, 160.7, 158.8, 131.4, 
122.5, 111.6, 106.9, 94.6, 93.9, 91.2, 56.7, 56.3, 33.2, 25.8, 21.6, 17.8; HRMS (FAB) m/z 
325.1668 [M + H]+ (calcd for C17H25O6, 325.1651).
1-[2-Methoxy-4,6-bis(methoxymethoxy)-3-(3-methylbut-2-enyl)phenyl]ethanone
—To a solution of di-MOM ether (132.6 mg, 0.41 mmol) in anhydrous DMF (5.0 mL) were 
added K2CO3 (360.0 mg, 2.61 mmol) and iodomethane (0.08 mL, 1.23 mmol). The mixture 
was heated at reflux temperature for 2.5 h under N2. After cooling to room temperature, the 
reaction was quenched with H2O (10.0 mL) and extracted with EtOAc (3 × 15 mL). The 
combined organic layers were washed with brine, dried over Na2SO4, and concentrated in 
vacuo. The residue was chromatographed on silica gel with EtOAc/n-hexane (1:5) to afford 
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the methyl ether (104.6 mg, 76%) as a yellow oil: 1H NMR (600 MHz, CDCl3) δ 6.70 (1H, 
s), 5.19 (2H, s), 5.17–5.14 (1H, m), 5.14 (2H, s), 3.72 (3H, s), 3.47 (3H, s), 3.46 (3H, s), 
3.29 (2H, d, J = 7.2 Hz), 2.52 (3H, s), 1.76 (3H, s), 1.67 (3H, s); 13C NMR (150 MHz, 
CDCl3) δ 202.2, 157.2, 156.1, 153.0, 131.3, 123.0, 120.8, 118.3, 97.9, 95.1, 94.3, 63.1, 56.4, 
56.2, 32.6, 25.7, 22.7, 17.8; HRMS (FAB) m/z 339.1777 [M + H]+ (calcd for C18H27O6, 
339.1808).
1-[4,6-Dihydroxy-2-methoxy-3-(3-methylbut-2-enyl)-phenyl]ethanone (20)—To a 
solution of 1-[2-methoxy-4,6-bis-(methoxymethoxy)-3-(3-methylbut-2-
enyl)phenyl]ethanone (54.7 mg, 0.16 mmol) in anhydrous MeOH (3.0 mL) was added 3 N 
HCl (0.6 mL), and the mixture was heated at reflux temperature for 1.5 h under N2. The 
mixture was cooled to room temperature and stirred for 15 min, quenched with H2O (10.0 
mL), and extracted with EtOAc (3 × 15 mL). The combined organic layers were washed 
with brine, dried over Na2SO4, and concentrated in vacuo. The residue was 
chromatographed on silica gel with EtOAc/n-hexane (1:6) to afford the target 20 (31.2 mg, 
77%) as a colorless solid: 1H NMR (600 MHz, CDCl3) δ 13.2 (1H, s), 6.53 (1H, s), 6.22 
(1H, s), 5.23–5.21 (1H, m), 3.74 (3H, s), 3.35 (2H, d, J = 7.2 Hz), 2.69 (3H, s), 1.82 (3H, s), 
1.75 (3H, s); 13C NMR (150 MHz, CDCl3) δ 203.7, 164.1, 162.6, 161.4, 135.0, 121.9, 
113.2, 109.5, 100.5, 62.8, 31.0, 25.8, 22.7, 18.0; HRMS (FAB) m/z 251.1290 [M + H]+ 
(calcd for C14H19O4, 251.1283).
1-(3,7-Dihydroxy-5-methoxy-2,2-dimethylchroman-6-yl)-ethanone (21)—To a 
solution of 20 (29.2 mg, 0.12 mmol) in anhydrous CH2Cl2 (3.0 mL) was added 75% m-
CPBA (31.7 mg, 0.14 mmol) at 0 °C, and the mixture was stirred for 20 min at room 
temperature. After consumption of 20 (TLC), montmorillonite K10 (29.2 mg) was added 
and the mixture was stirred for 30 min at room temperature. The mixture was filtered and 
washed with EtOAc. The organic layer was washed with saturated Na2CO3, H2O, and brine, 
dried over Na2SO4, and concentrated in vacuo. The residue was chromatographed on silica 
gel with EtOAc/n-hexane (1:2) to afford 21 (26.4 mg, 85%) as a colorless solid: 1H NMR 
(600 MHz, CDCl3) δ 13.0 (1H, s), 6.20 (1H, s), 3.83–3.82 (1H, m), 3.78 (3H, s), 2.95 (1H, 
dd, J = 16.8, 5.4 Hz), 2.71 (1H, dd, J = 16.8, 6.6 Hz), 2.67 (3H, s), 1.99 (1H, d, J = 4.2 Hz), 
1.37 (3H, s), 1.36 (3H, s); 13C NMR (150 MHz, CDCl3) δ 203.2, 163.7, 162.1, 160.2, 109.7, 
104.9, 101.2, 78.1, 69.1, 61.5, 31.1, 26.0, 25.1, 21.8; HRMS (FAB) m/z 267.1228 [M + H]+ 
(calcd for C14H19O5, 267.1232).
1-[3-Hydroxy-5-methoxy-2,2-dimethyl-7-(3-methylbut-2-enyloxy)chroman-6-
yl]ethanone—To a solution of 21 (28.3 mg, 0.11 mmol) and K2CO3 (59.7 mg, 0.43 mmol) 
in acetone (2.0 mL) was added prenyl bromide (0.02 mL, 0.17 mmol), and the mixture was 
heated at reflux temperature for 12.5 h under N2. The mixture was cooled to room 
temperature, filtered, washed with EtOAc, and concentrated in vacuo. The residue was 
chromatographed on silica gel with EtOAc/n-hexane (1:2) to afford the product (34.3 mg, 
97%) as a colorless oil: 1H NMR (600 MHz, CDCl3) δ 6.21 (1H, s), 5.43–5.41 (1H, m), 4.45 
(2H, d, J = 7.2 Hz), 3.82–3.79 (1H, m), 3.74 (3H, s), 2.91 (1H, dd, J = 16.8, 4.8 Hz), 2.68 
(1H, dd, J = 13.8, 6.0 Hz), 2.50 (3H, s), 1.77 (3H, s), 1.69 (3H, s), 1.67 (1H, d, J = 6.6 Hz), 
1.36 (3H, s), 1.32 (3H, s); 13C NMR (150 MHz, CDCl3) δ 202.1, 156.8, 156.1, 155.2, 137.9, 
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119.3, 118.8, 105.0, 101.3, 97.2, 69.1, 65.5, 62.1, 32.6, 26.0, 25.7, 24.8, 21.9, 18.2; HRMS 
(FAB) m/z 335.1870 [M + H]+ (calcd for C19H27O5, 335.1858).
(rac)-Acronyculatin I (1)—To a solution of 1-[3-hydroxy-5-methoxy-2,2-dimethyl-7-(3-
methylbut-2-enyloxy)chroman-6-yl]-ethanone (34.3 mg, 0.10 mmol) in anhydrous CH2Cl2 
(0.5 mL) was added montmorillonite K10 (34.4 mg) at 0 °C, and the mixture was stirred for 
3.0 h at room temperature. The mixture was filtered, washed with EtOAc, and concentrated 
in vacuo. The residue was purified using preparative TLC with EtOAc/n-hexane (1:1) to 
afford 1 (18.8 mg, 55%) as a colorless solid. The physical data (1H NMR, 13C NMR, 
HRMS) were essentially identical to the reported data for the natural product.9
(rac)-Acronyculatin J (2)—To a solution of 1 (7.6 mg, 0.02 mmol) in EtOH (0.5 mL) 
was added Pd/C (3.6 mg). The reaction mixture was sealed and stirred at room temperature 
for 2.0 h under H2. The mixture was filtered through Celite, washed with EtOAc, and 
concentrated in vacuo. The residue was purified using preparative TLC with CHCl3/MeOH 
(30:1) to afford 2 (5.7 mg, 75%) as a colorless oil. The physical data (1H NMR, 13C NMR, 
HRMS) were essentially identical to the reported data for the natural product.9
1-[2-Allyloxy-4,6-bis(methoxymethoxy)phenyl]ethanone—To a mixture of 9 (71.9 
mg, 0.28 mmol) and K2CO3 (152.6 mg, 1.10 mmol) in acetone (3.0 mL) was added 
dropwise a solution of allyl bromide (0.07 mL, 0.83 mmol) in acetone (0.9 mL). The 
reaction mixture was stirred under reflux for 28 h. The mixture was cooled to room 
temperature, filtered, and evaporated in vacuo. The residue was extracted with CH2Cl2 (3 × 
15 mL). The combined organic layers were washed with saturated NaHCO3 and brine, dried 
over Na2SO4, and concentrated in vacuo. The residue was purified with column 
chromatography on silica gel to obtain the product (72.3 mg, 0.24 mmol, 86%) as a pale 
yellow oil: 1H NMR (400 MHz, CDCl3) δ 6.46 (1H, s, J = 2.0 Hz), 6.31 (1H, d, J = 2.0 Hz), 
6.04–5.94 (1H, m), 5.40–5.35 and 5.28–5.25 (2H, each m), 5.14 (4H, d, J = 4.4 Hz), 4.53–
4.51 (2H, m), 3.47 (6H, d, J = 5.6 Hz), 2.49 (3H, s); 13C NMR (150 MHz, CDCl3) δ 201.6, 
159.6, 156.8, 155.3, 132.6, 117.7, 116.2, 96.2, 95.0, 94.8, 94.4, 69.4, 56.3, 56.2, 32.5; 
HRMS (FAB) m/z 297.1338 [M + H]+ (calcd for C15H21O6, 297.1355).
1-[2-Hydroxy-3-(2-propenyl)-4,6-bis(methoxymethoxy)-phenyl]ethanone (22)—
A solution of 1-[2-allyloxy-4,6-bis-(methoxymethoxy)phenyl]ethanone (104.6 mg, 0.35 
mmol) in N,N-diethylaniline (0.5 mL) was irradiated in a microwave oven for 1 h at 210 °C. 
The mixture was cooled to room temperature and the reaction quenched with ice-cooled 
15% aquoeus HCl. The residue was extracted three times with CH2Cl2 (3 × 15 mL). The 
combined organic layers were washed with H2O, dried over Na2SO4, and concentrated in 
vacuo. The residue was purified with column chromatography on silica gel to obtain 22 
(83.5 mg, 0.28 mmol, 83% based on recovery of starting material) as a pale yellow oil: 1H 
NMR (400 MHz, CDCl3) δ 13.9 (1H, s), 6.40 (1H, s), 5.98–5.90 (1H, m), 5.26 (2H, s), 5.23 
(2H, s), 5.03–4.93 (2H, m), 3.52 (3H, s), 3.47 (3H, s), 3.38–3.36 (2H, m), 2.66 (3H, s).
1-[2-Methoxy-3-(2-propenyl)-4,6-bis(methoxymethoxy)-phenyl]ethanone—
Iodomethane (0.023 mL, 0.37 mmol) was added to a solution of 22 (43.1 mg, 0.15 mmol) 
and K2CO3 (104.3 mg, 0.75 mmol) in DMF (2.0 mL), and the mixture was heated under 
Morita et al. Page 9
J Nat Prod. Author manuscript; available in PMC 2017 November 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
reflux for 3 h. The mixture was cooled to room temperature and quenched with H2O (20 
mL). The residue was extracted with EtOAc (3 × 15 mL), and the combined organic layers 
were washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue was 
purified using column chromatography on silica gel to obtain the product (39.6 mg, 0.13 
mmol, 87% based on recovery of starting material) as a pale yellow oil: 1H NMR (400 MHz, 
CDCl3) δ 6.71 (1H, s), 6.00–5.91 (1H, m), 5.17 (2H, s), 5.14 (2H, s), 5.00–4.95 (2H, m), 
3.12 (3H, s), 3.46 (3H, s), 3.46 (3H, s), 3.36–3.35 (2H, m), 2.51 (3H, s); 13C NMR (150 
MHz, CDCl3) δ 202.2, 157.3, 156.3, 153.3, 136.8, 120.8, 116.4, 114.6, 97.8, 95.0, 94.4, 
63.4, 56.4, 56.3, 32.6, 27.7; HRMS (FAB) m/z 311.1491 [M + H]+ (calcd for C16H23O6, 
311.1495).
1-[2-Hydroxy-3-(2-propenyl)-4,6-dihydroxyphenyl]-ethanone (23)—A solution of 
1-[2-methoxy-3-(2-propenyl)-4,6-bis(methoxymethoxy)phenyl]ethanone (33.7 mg, 0.11 
mmol) in MeOH (1.0 mL) was treated with HCl (0.09 mL, 0.18 mmol), and the mixture was 
heated under reflux for 7 h. The mixture was cooled to room temperature, quenched with 
H2O (10 mL), and extracted with EtOAc (3 × 10 mL). The combined organic layers were 
washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue was purified 
with column chromatography on silica gel to obtain 23 (19.3 mg, 0.09 mmol, 90%) as a 
colorless oil: 1H NMR (400 MHz, CDCl3) δ 13.2 (1H, s), 6.25 (1H, s), 6.09–6.02 (1H, m), 
5.61 (1H, s), 5.21–5.18 and 5.15–5.14 (2H, each m), 3.75 (3H, s), 3.44–3.41 (2H, m), 2.70 
(3H, s); 13C NMR (150 MHz, CDCl3) δ 203.6, 164.4, 161.9, 161.9, 136.2, 116.4, 111.0, 
109.8, 100.6, 63.1, 31.0, 27.8.
(rac)-Acronyculatin N (5)—A solution of 23 (4.3 mg, 0.02 mmol) in 1,4-dioxane (0.26 
mL) was treated with 2% OsO4/tert-BuOH (50 μL, 0.004 mmol), and the mixture was stirred 
in the dark at room temperature. After 30 min, 1.3% NaIO4/H2O (0.8 mL, 0.05 mmol) was 
added dropwise. The reaction was quenched with H2O (5 mL) and extracted with EtOAc (3 
× 7 mL). The combined organic layers were washed with 20% aqueous Na2S2O3, dried over 
Na2SO4, and concentrated in vacuo. The residue was purified with column chromatography 
on silica gel to obtain 5 (3.1 mg, 0.013 mmol, 65%) as a colorless solid. The physical data 
(1H NMR, 13C NMR, HRMS) were essentially identical to the reported data for the natural 
product.9
1-[2,4-Bis(tert-butyldimethylsilyloxy)-6-hydroxy-3,5-bis(3-methylbut-2-
enyl)phenyl]ethanone—To a solution of 24 (95.9 mg, 0.32 mmol) in anhydrous N,N-
dimethylformamide (1.0 mL) were added 4-dimethylaminopyridine (3.8 mg, 0.03 mmol) 
and imidazole (68 mg, 1.00 mmol) at room temperature. The mixture was cooled to 0 °C, 
and then TBSCl (101.0 mg, 0.67 mmol) was added. The resulting mixture was allowed to 
warm to room temperature and was stirred for 45 min. The reaction mixture was adjusted to 
pH 1 by addition of 1 N HCl and extracted with EtOAc (3 × 10 mL). The combined organic 
layers were washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue 
was chromatographed on silica gel with CH2Cl2/n-hexane (1:6) to afford the title compound 
(51.7 mg, 31%) as a yellow oil: 1H NMR (600 MHz, CDCl3) δ 12.0 (1H, s), 5.17–5.14 (2H, 
m), 3.26 (2H, d, J = 6.6 Hz), 3.20 (2H, d, J = 5.4 Hz), 2.58 (3H, s), 1.72 (3H, s), 1.68 (3H, 
s), 1.66 (3H, s), 1.64 (3H, s), 1.05 (9H, s), 1.01 (9H, s), 0.19 (6H, s), 0.04 (6H, s); 13C NMR 
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(150 MHz, CDCl3) δ 204.5, 158.9, 158.0, 153.3, 131.5, 131.1, 124.3, 124.3, 123.2, 117.3, 
114.7, 112.6, 31.4, 26.1, 25.9, 25.7, 25.4, 24.4, 23.5, 18.8, 18.2, 18.1, 18.0, −3.03, −4.19; 
HRMS (FAB) m/z 533.3443 [M + H]+ (calcd for C30H53O4Si2, 533.3482).
1-[2,4-Bis(tert-butyldimethylsilyloxy)-6-methoxy-3,5-bis(3-methylbut-2-
enyl)phenyl]ethanone—A 60% NaH (10.0 mg) solution was washed with n-hexane (0.5 
mL) and dissolved in anhydrous THF (0.5 mL). The mixture was cooled to 0 °C, and 1-[2,4-
bis(tert-butyldimethylsilyloxy)-6-hydroxy-3,5-bis(3-methylbut-2-enyl)phenyl]ethanone 
(22.6 mg, 0.04 mmol) in anhydrous THF (0.5 mL) and dimethyl sulfate (0.02 mL, 0.19 
mmol) were added under N2. The mixture was allowed to warm to room temperature and 
stirred for 3.0 h. The reaction mixture was then adjusted to pH 8 by addition of saturated 
aqueous NH4Cl and extracted with EtOAc (3 × 10 mL). The combined organic layers were 
washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue was 
chromatographed on silica gel with EtOAc/n-hexane (1:20) to afford the product (21.1 mg, 
91%) as a colorless oil: 1H NMR (600 MHz, CDCl3) δ 5.17–5.13 (2H, m), 3.65 (3H, s), 3.24 
(4H, m), 2.50 (3H, s), 1.69 (3H, s), 1.66 (3H, s), 1.65 (3H, s), 1.63 (3H, s), 1.00 (9H, s), 0.99 
(9H, s), 0.21 (6H, s), 0.07 (6H, s); 13C NMR (150 MHz, CDCl3) δ 202.7, 154.4, 154.0, 
149.1, 131.1, 130.9, 123.9, 123.6, 121.7, 121.2, 62.7, 32.9, 26.1, 26.0, 25.6, 25.4, 24.8, 24.0, 
18.7, 18.4, 18.1, 18.0, −3.20, −3.72; HRMS (FAB) m/z 547.3659 [M + H]+ (calcd for 
C30H55O4Si2, 547.3639).
1-[4-(tert-Butyldimethylsilyloxy)-2-hydroxy-6-methoxy-3,5-bis(3-methylbut-2-
enyl)phenyl]ethanone (25)—To a solution of 1-[2,4-bis(tert-butyldimethylsilyloxy)-6-
methoxy-3,5-bis(3-methylbut-2-enyl)phenyl]ethanone (14.8 mg, 0.03 mmol) in anhydrous 
THF (0.2 mL) were added TFA (0.1 mL) and H2O (0.1 mL). The mixture was stirred at 
room temperature for 1.0 h. The reaction mixture was adjusted to pH 7 by addition of 
saturated aqueous NaHCO3 and extracted with CH2Cl2 (3 × 5 mL). The combined organic 
layers were washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue 
was purified using preparative TLC with EtOAc/n-hexane (1:12) to afford 25 (12.7 mg, 
92%) as a yellow oil: 1H NMR (600 MHz, CDCl3) δ 13.2 (1H, s), 5.17–5.14 (1H, m), 5.13–
5.11 (1H, m), 3.66 (3H, s), 3.26 (4H, t, J = 6.6 Hz), 2.68 (3H, s), 1.72 (3H, s), 1.71 (3H, s), 
1.67 (3H, s), 1.66 (3H, s), 1.00 (9H, s), 0.21 (6H, s); 13C NMR (150 MHz, CDCl3) δ 203.9, 
161.7, 159.3, 158.8, 131.8, 131.1, 123.7, 122.8, 118.4, 117.3, 110.4, 62.5, 31.0, 26.1, 25.7, 
25.5, 23.8, 23.5, 18.9, 18.0, −3.05; HRMS (FAB) m/z 433.2733 [M + H]+ (calcd for 
C25H41O4Si, 433.2774).
2-Acetyl-5-(tert-butyldimethylsilyloxy)-3-methoxy-4,6-bis(3-methylbut-2-
enyl)phenyl Acetate (26)—To a solution of 25 (58.9 mg, 0.14 mmol) in pyridine (1.0 
mL) were added DMAP (2.3 mg, 0.02 mmol) and Ac2O (0.06 mL, 0.68 mmol), and the 
mixture was stirred at room temperature for 1.0 h. The reaction mixture was adjusted to pH 
4 by addition of 1 N HCl and extracted with EtOAc (3 × 10 mL). The combined organic 
layers were washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue 
was chromatographed on silica gel with EtOAc/n-hexane (1:10) to afford 26 (56.4 mg, 87%) 
as a colorless oil: 1H NMR (600 MHz, CDCl3) δ 5.14–5.12 (1H, m), 5.02–4.99 (1H, m), 
3.65 (3H, s), 3.30 (2H, d, J = 6.6 Hz), 3.19 (2H, d, J = 6.0 Hz), 2.52 (3H, s), 2.17 (3H, s), 
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1.71 (3H, s), 1.67 (3H, s), 1.67 (3H, s), 1.66 (3H, s), 1.00 (9H, s), 0.19 (6H, s); 13C NMR 
(100 MHz, CDCl3) δ 201.5, 169.3, 155.6, 154.1, 144.9, 131.6, 131.5, 124.7, 123.0, 122.5, 
122.4, 62.8, 31.3, 26.0, 25.6, 25.5, 24.5, 24.1, 20.8, 18.8, 18.0, 17.9, −3.11; HRMS (FAB) 
m/z 475.2862 [M + H]+ (calcd for C27H43O5Si, 475.2880).
2-Acetyl-5-[(tert-butyldimethylsilyl)oxy]-6-[(3,3-dimethyloxiran-2-yl)methyl)]-3-
methoxy-4-(3-methylbut-2-en-1-yl)phenyl Acetate (28a) and 2-Acetyl-5-[(tert-
butyldimethylsilyl)oxy]-4-[(3,3-dimethyloxiran-2-yl)methyl]-3-methoxy-6-(3-
methylbut-2-en-1-yl)phenyl Acetate (28b)—To a solution of 26 (12.9 mg, 0.03 mmol) 
in anhydrous CH2Cl2 (0.5 mL) was added 75% m-CPBA (6.2 mg, 0.03 mmol) at −70 °C, 
and the mixture was stirred for 30 min. The reaction mixture was adjusted to pH 7 by 
addition of saturated aqueous Na2CO3 and extracted with CH2Cl2 (3 × 5 mL). The 
combined organic layers were washed with brine, dried over Na2SO4, and concentrated in 
vacuo. The residue was chromatographed on silica gel with EtOAc/n-hexane (1:5) to afford 
a mixture of the target compounds 28a and 28b [6.1 mg, 77% (based on recovery of starting 
material)] as a yellow oil.
5-Acetyl-2-(2-hydroxypropan-2-yl)-6-methoxy-7-(3-methyl-but-2-en-1-yl)-2,3-
dihydrobenzofuran-4-yl Acetate (29) and 5-Acetyl-2-(2-hydroxypropan-2-yl)-4-
methoxy-7-(3-methylbut-2-en-1-yl)-2,3-dihydrobenzofuran-6-yl Acetate (30)—To 
a mixture of 28a and 28b (6.1 mg, 0.01 mmol) in anhydrous THF (0.5 mL) were added 
HOAc (2.0 μL, 0.03 mmol) and TBAF (15.0 μL, 0.015 mmol), and the mixture was stirred at 
0 °C for 10 min under Ar. To the mixture was added p-TsOH (2.4 mg, 0.01 mmol), and the 
mixture was stirred for 1.0 h. The mixture was adjusted to pH 7 by addition of saturated 
aqueous NaHCO3 and extracted with EtOAc (3 × 5 mL). The combined organic layers were 
washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue was purified 
using preparative TLC with EtOAc/n-hexane (1:2) to afford 29 (1.3 mg, 27%) and 30 (2.9 
mg, 64%) as yellow oils.
5-Acetyl-2-(2-hydroxypropan-2-yl)-6-methoxy-7-(3-methyl-but-2-enyl)-2,3-
dihydrobenzofuran-4-yl Acetate (29)—1H NMR (600 MHz, CDCl3) δ 5.20–5.17 (1H, 
m), 4.68 (1H, t, J = 8.4 Hz), 3.70 (3H, s), 3.28 (2H, d, J = 7.8 Hz), 3.02–2.99 (2H, m), 2.51 
(3H, s), 2.25 (3H, s), 1.76 (3H, s), 1.70 (3H, s), 1.30 (3H, s), 1.19 (3H, s); 13C NMR (100 
MHz, CDCl3) δ 168.6, 166.1, 160.8, 157.5, 153.2, 132.3, 121.7, 116.3, 115.3, 90.5, 77.2, 
71.8, 63.4, 31.5, 28.4, 25.7, 25.6, 24.0, 23.0, 20.7, 17.8; HRMS (FAB) m/z 377.1975 [M + 
H]+ (calcd for C21H29O6, 377.1964).
5-Acetyl-2-(2-hydroxypropan-2-yl)-4-methoxy-7-(3-methyl-but-2-enyl)-2,3-
dihydrobenzofuran-6-yl Acetate (30)—1H NMR (600 MHz, CDCl3) δ 5.11–5.08 (1H, 
m), 4.66 (1H, t, J = 9.6 Hz), 3.86 (3H, s), 3.29–3.27 (2H, m), 3.16 (1H, dd, J = 15.0, 7.8 Hz), 
3.10 (1H, dd, J = 14.4, 6.6 Hz) 2.46 (3H, s), 2.24 (3H, s), 1.72 (3H, s), 1.67 (3H, s), 1.35 
(3H, s), 1.23 (3H, s); 13C NMR (100 MHz, CDCl3) δ 200.3, 169.5, 161.1, 152.8, 146.5, 
132.2, 121.1, 114.0, 112.1, 90.1, 77.2, 71.6, 59.9, 31.8, 29.4, 26.0, 25.7, 24.3, 23.4, 20.7, 
17.8; HRMS (FAB) m/z 377.1958 [M + H]+ (calcd for C21H29O6, 377.1964).
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(rac)-Acronyculatin O (6)—To a solution of 29 (2.0 mg, 0.005 mmol) in anhydrous 
MeOH (0.1 mL) was added Ba(OH)2 (0.1 mL, 0.01 mmol, 0.1 M in MeOH), and the 
mixture was stirred for 30 min at room temperature. The mixture was directly purified using 
preparative TLC with CHCl3/MeOH (20:1) to afford 6 (1.1 mg, 56%) as a colorless solid. 
The physical data (1H NMR, 13C NMR, HRMS) were essentially identical to the reported 
data for the natural product.9
(rac)-Acronyculatin B (7)—To a solution of 30 (5.3 mg, 0.02 mmol) in anhydrous MeOH 
(0.2 mL) was added Ba(OH)2 (0.2 mL, 0.02 mmol, 0.1 M in MeOH), and stirring continued 
for 30 min at room temperature. The mixture was directly purified using preparative TLC 
with CHCl3/MeOH (20:1) to afford 7 (2.5 mg, 53%) as a colorless solid. The physical data 
(1H NMR, 13C NMR, HRMS) were essentially identical to the reported data for the natural 
product.9
In Vitro EBV-EA Activation Experiments
The anti-tumor-promoting activities of compounds were assessed using the EBV-EA 
activation assay in the presence of 32 pmol/mL TPA as described before.26,27 The average 
EBV-EA induction of the test compound was determined as a ratio relative to the control. 
The viability of treated Raji cells was evaluated by trypan blue staining.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Scheme 1. Total Synthesis of Racemic Acetophenone Monomers 1–5a
aConditions: (a) MOMCl, DIPEA, CH2Cl2, rt; (b) prenyl-Br, K2CO3, acetone, reflux; (c) 
PhNEt2, microwave, 210 °C; (d) MeI, K2CO3, DMF, reflux; (e) 3 N HCl/MeOH (1:10), 
reflux; (f) 3 N HCl/MeOH (1:5), reflux; (g) mCPBA, CH2Cl2, rt, 20 min, then 
montmorillonite K10 (M-K10), 30 min; (h) M-K10, CH2Cl2, microwave, 60 °C; (i) M-K10, 
CH2Cl2, 0 °C to rt; (j) Pd/C, H2, EtOH, rt; (k) prenyl-Br, DBU, THF, rt; (l) allyl-Br, K2CO3, 
acetone, reflux; (m) 2% OsO4, NaIO4, 1,4-dioxane, rt. *rsm: recovery of starting material.
Morita et al. Page 15
J Nat Prod. Author manuscript; available in PMC 2017 November 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Scheme 2. Preparation of Racemic Acetophenone Monomers 6 and 7a
aConditions: (a) prenyl-Br, 10% KOHaq, CH2Cl2, rt, 1.5 h, 46%; (b) TBSCl, imidazole, 
DMAP, DMF, 85 °C, 45 min, 31%; (c) Me2SO4, NaH, THF, rt, 3.0 h, 91%; (d) TFA/H2O, 
THF, rt, 1.0 h, 92%; (e) Ac2O, DMAP, Py, rt, 1.0 h, 87%; (f) mCPBA, CH2Cl2, −70 °C, 30 
min; (g) TBAF, HOAc, THF, 0 °C to rt, 1 h, 27% for 29, 64% for 30; (h) 0.1 M Ba(OH)2, 
MeOH, 30 min, rt, 56% for 6, 53% for 7.
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